Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry. Volume 4



Library of Congress Cataloging-in-Publication Data

Names: Pesti, Jaan A., 1954- editor. | Abdel-Magid, Ahmed F., 1947- editor. | Vaidyanathan, Rajappa, editor. | American Chemical Society, issuing body. | American Chemical Society. Division of Organic Chemistry, sponsoring body.

Title: Complete accounts of integrated drug discovery and development:

recent examples from the pharmaceutical industry, vol. 4/

Jaan A. Pesti, editor, Pharma Resource Group, Inc., Drexel Hill, Pennsylvania, United States,

Ahmed F. Abdel-Magid, editor, Therachem Research Medilab, LLC, Chelsea,

Alabama, United States, Rajappa Vaidyanathan, editor, Medicines for All Institute,

Virginia Commonwealth University, Richmond, Virginia, United States;

sponsored by the ACS Division of Organic Chemistry.

Description: Washington, DC: American Chemical Society, [2018-] | Series:

ACS symposium series; 1423 | Includes bibliographical references and index.

Identifiers: LCCN 2018048857 (print) | LCCN 2018050283 (ebook) | ISBN

9780841297326 (ebook) | ISBN 9780841297333 (hardcover OP) | ISBN 9781713887959 (pod)

Subjects: LCSH: Drug development. | Pharmaceutical industry. | Pharmaceutical technology.

Classification: LCC RM301.25 (ebook) | LCC RM301.25 .C66 2018 (print) | DDC

615.1/9--dc23

LC record available at https://lccn.loc.gov/2018048857

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48n1984.

Copyright © 2022 American Chemical Society

All Rights Reserved. Reprographic copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Act is allowed for internal use only, provided that a per-chapter fee of \$40.25 plus \$0.75 per page is paid to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. Republication or reproduction for sale of pages in this book is permitted only under license from ACS. Direct these and other permission requests to ACS Copyright Office, Publications Division, 1155 16th Street, N.W., Washington, DC 20036.

The citation of trade names and/or names of manufacturers in this publication is not to be construed as an endorsement or as approval by ACS of the commercial products or services referenced herein; nor should the mere reference herein to any drawing, specification, chemical process, or other data be regarded as a license or as a conveyance of any right or permission to the holder, reader, or any other person or corporation, to manufacture, reproduce, use, or sell any patented invention or copyrighted work that may in any way be related thereto. Registered names, trademarks, etc., used in this publication, even without specific indication thereof, are not to be considered unprotected by law.

PRINTED IN THE UNITED STATES OF AMERICA

Contents

Pre	efaceix
1.	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene Matthew Maddess, John McIntosh, and Wonsuk Chang
2.	Discovery and Chemical Development of Adafosbuvir, a Nucleoside Phosphoramidate Prodrug for the Treatment of Hepatitis C Infection
3.	Discovery and Development of a Highly Potent, Orally Bioavailable Estrogen Receptor Full Antagonist and Degrader: Giredestrant (GDC-9545) for Estrogen Receptor-Positive Breast Cancer
4.	A Twisted Road to the Discovery and Chemical Development of BMS-986142: A Reversible Inhibitor of BTK Conformationally Constrained by Two Rotationally Stable Atropisomeric Axes
5.	Discovery of AMG 232, a Small Molecule Disrupting the p53-MDM2 Protein–Protein Interaction and Development of a Validation-Ready Process for Its Manufacture
6.	The Discovery and Chemical Development of BMS-986251: A Selective RORγt Inverse Agonist for the Potential Treatment of Autoimmune Diseases
7.	Discovery and Chemical Development of Amcenestrant: An Oral Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
8.	Development and Optimization of the Manufacturing Process for RNA-Splicing Modifier Risdiplam RG7916
9.	Past, Present, and Future: A Changing Paradigm for Process Chemistry

Editors' Biographies	357
Indexes	
Author Index	361
Subject Index	363